A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5)

Acta Haematol. 2017;138(4):198-200. doi: 10.1159/000484077. Epub 2017 Nov 24.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Autoantigens / chemistry
  • Autoantigens / genetics*
  • Cell Cycle Proteins / chemistry
  • Cell Cycle Proteins / genetics*
  • Chromosomes, Human, Pair 5 / genetics
  • Chromosomes, Human, Pair 8 / genetics
  • Humans
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / genetics*
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelomonocytic, Chronic / drug therapy
  • Leukemia, Myelomonocytic, Chronic / genetics*
  • Male
  • Middle Aged
  • Mutagenesis, Insertional
  • Oncogene Proteins, Fusion / chemistry
  • Oncogene Proteins, Fusion / genetics*
  • Protein Kinase Inhibitors / therapeutic use
  • RNA, Neoplasm / genetics
  • Receptor, Platelet-Derived Growth Factor beta / chemistry
  • Receptor, Platelet-Derived Growth Factor beta / genetics*

Substances

  • Antineoplastic Agents
  • Autoantigens
  • Cell Cycle Proteins
  • Oncogene Proteins, Fusion
  • PCM1 protein, human
  • Protein Kinase Inhibitors
  • RNA, Neoplasm
  • Imatinib Mesylate
  • PDGFRB protein, human
  • Receptor, Platelet-Derived Growth Factor beta

Supplementary concepts

  • Pdgfrb-Associated Chronic Eosinophilic Leukemia